Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Millennium Pharmacon International Tbk's EBIT per Share for the
three
months ended in Mar. 2026 was Rp22.16.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was Rp86.97.
During the past 12 months, the average EBIT per Share Growth Rate of PT Millennium Pharmacon International Tbk was 9.60% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 13.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 17.60% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 3.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
ISX:SDPC'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -14 Med: 14.6 Max: 32.8
Current: 13.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of PT Millennium Pharmacon International Tbk was 32.80% per year. The lowest was -14.00% per year. And the median was 14.60% per year.
ISX:SDPC's 3-Year EBIT Growth Rate is ranked better than 71.03% of 107
companies
in the Medical Distribution industry
Industry Median: 2.7
vs ISX:SDPC: 13.40
PT Millennium Pharmacon International Tbk (ISX:SDPC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
PT Millennium Pharmacon International Tbk EBIT per Share Related Terms
PT Millennium Pharmacon International Tbk EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Millennium Pharmacon International Tbk EBIT per Share Chart
PT Millennium Pharmacon International Tbk Annual Data
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp86.97
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Millennium Pharmacon International Tbk (ISX:SDPC) has a EBIT per Share of Rp86.97 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PT Millennium Pharmacon International Tbk and its competitors. According to the industry distribution chart, PT Millennium Pharmacon International Tbk ranks #31 out of 107 companies in the Medical Distribution industry, placing it in the top 29%.
Is PT Millennium Pharmacon International Tbk's EBIT per Share too high?
PT Millennium Pharmacon International Tbk's current EBIT per Share is Rp86.97. Based on the distribution chart, PT Millennium Pharmacon International Tbk ranks #31 out of 107 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, PT Millennium Pharmacon International Tbk has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Millennium Pharmacon International Tbk's EBIT per Share compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Millennium Pharmacon International Tbk ranks #31 out of 107 companies for EBIT per Share. This puts PT Millennium Pharmacon International Tbk in the upper half of its industry. The industry median EBIT per Share is 2.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Distribution company?
The median EBIT per Share among Medical Distribution companies is 2.70, based on 107 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PT Millennium Pharmacon International Tbk and its competitors. For the Medical Distribution industry, the median EBIT per Share is 2.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Millennium Pharmacon International Tbk's current EBIT per Share is Rp86.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Millennium Pharmacon International Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk (ISX:SDPC) is currently considered Fairly Valued. The stock's GF Value™ is Rp166.83, compared to a current price of Rp181.00 — trading 8.5% above its estimated fair value. The current EBIT per Share is Rp86.97. PT Millennium Pharmacon International Tbk's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For PT Millennium Pharmacon International Tbk (ISX:SDPC), the current EBIT per Share is Rp86.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Millennium Pharmacon International Tbk (ISX:SDPC) Overvalued in 2026?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk stock appears to be overvalued.
The current stock price of Rp181.00 is trading 8.5% above its estimated GF Value™ of Rp166.83.
GuruFocus considers PT Millennium Pharmacon International Tbk to be Fairly Valued.
Key valuation signals for ISX:SDPC:
EBIT per Share: Rp86.97
GF Value™: Rp166.83 vs. price of Rp181.00 (8.5% above fair value)
No single metric tells the full story. See the ISX:SDPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressJl. Sultan Iskandar Muda No 18/Jl. Bungur No. 1, Crown Bungur Arteri Lantai 2-4, Kel. Kebayoran Lama Selatan, Kec. Kebayoran Lama, South Jakarta, Jakarta, IDN, 12240
PT Millennium Pharmacon International Tbk is engaged in distributing medicines, food supplements, and medical disposables. The group's operating segments are Prescription medicine, Non-prescription medicine, Medical Disposables, and others, of which the majority of revenue is derived from the Prescription Medicine segment. The company's geographical segments are Jawa, Sumatra, Kalimantan, Sulawesi, and Bali & Lombok.
79GF Score
Get the complete analysis for ISX:SDPC
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SDPC has been successfully added to your 
